United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?Zacks Investment Research • 03/10/26
United Therapeutics Corporation (UTHR) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/09/26
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase ProgramBusiness Wire • 03/09/26
United Therapeutics Corporation to Present at the Leerink Global Healthcare ConferenceBusiness Wire • 03/03/26
United Therapeutics Corporation (UTHR) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/02/26
United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension TranscriptSeeking Alpha • 03/02/26
United Therapeutics' blood pressure drug meets main, secondary goals in late-stage studyReuters • 03/02/26
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant EfficacyBusiness Wire • 03/02/26
These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 EarningsBenzinga • 02/26/26
United Therapeutics Q4 Earnings: Sky May Be The Limit For This Management TeamSeeking Alpha • 02/26/26
UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong GuidanceZacks Investment Research • 02/26/26
Compared to Estimates, United Therapeutics (UTHR) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/25/26
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire • 02/25/26
United Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care ConferenceBusiness Wire • 02/23/26
Unveiling United Therapeutics (UTHR) Q4 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 02/20/26
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026Business Wire • 02/11/26
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver FailureBusiness Wire • 01/26/26
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of DirectorsBusiness Wire • 01/22/26
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-TermZacks Investment Research • 01/16/26
United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26